Identification of Urinary Exosomal miRNAs for the Non-Invasive Diagnosis of Prostate Cancer.

BACKGROUND: Novel and non-invasive biomarkers with higher sensitivity and specificity for the diagnosis of prostate cancer (PCa) is urgently needed. In this study, we used next-generation sequencing (NGS) to characterize the genome-wide exosomal miRNA expression profiling in urine specimens and explored the diagnostic potential of urinary exosomal miRNAs for PCa.
METHODS: Urinary exosomal microRNA expression profiling was performed by next-generation sequencing (NGS) and then validated by quantitative real-time PCR.
RESULTS: Significant downregulation of urinary exosomal miR-375 was observed in PCa patients compared with healthy controls, while the expression levels of urinary exosomal miR-451a, miR-486-3p and miR-486-5p were found to be significantly up-regulated in the PCa patients. Furthermore, the expression level of urinary exosomal miR-375 showed a significant correlation with the clinical T-stage and bone metastasis of patients with PCa (P<0.05). Receiver operator characteristic curve demonstrated that the urinary exosomal miR-375, miR-451a, miR-486-3p and miR-486-5p levels can be used to differentiate PCa patients from healthy controls, with area under the curves (AUCs) of 0.788, 0.757, 0.704 and 0.796, respectively. The urinary exosomal miR-375 was found to be superior in discriminating between localized and metastatic PCa with an AUC of 0.806. Moreover, PCa patients can be distinguished from patients with benign prostatic hyperplasia by using a panel combining urinary exosomal miR-375 and miR-451a with an AUC of 0.726.
CONCLUSION: These findings demonstrate that the urinary exosomal miRNAs can serve as novel and non-invasive biomarkers for diagnosing and predicting the progression of PCa.

Background

Prostate cancer (PCa) is one of the most common malignant tumours in the male urinary system.1 Although the conventional biopsy is the gold standard for the diagnosis of this tumour, its application is limited due to its invasive procedure. Currently, prostate-specific antigen (PSA) is the most commonly used biomarker for prostate cancer screening. Serum PSA testing for the early detection of PCa, however, strongly depends on the patient’s age and the local prevalence of the disease.2 Most importantly, there are other factors in addition to PCa that can increase the PSA level, such as the presence of benign prostatic hyperplasia (BPH), infection and chronic inflammation,3 leading to a significant over-diagnosis and subsequent overtreatment of indolent PCa. The PSA level, Gleason score, and radiological features are difficult to predict the progression of PCa. Therefore, novel and non-invasive biomarkers with high sensitivity and specificity for the diagnosis of PCa are urgently needed. Exosomal microRNAs (miRNAs or miRs) in circulating body fluids have recently been reported to augment the diagnosis and management of various diseases, including cancer.4–7

Exosomes are small membrane-bound vesicles ranging in size from 30 to 100 nm, which are secreted by numerous cell types into the extracellular environment and can be found in biological fluids such as blood, semen, saliva and urine.8–10 Exosomes contain proteins and various types of RNA molecules including miRNAs. It has been reported that miRNA-rich exosomes can be taken up by neighbouring or distant cells, and subsequently modulate those recipient cells.11 Recent research has revealed that exosomal miRNA profiling can reflect its cell of origin.12,13 In particular, the exosomal miRNAs derived from urine have been identified in recent years.14,15 Recently, extensive attention has been focused on using exosomal miRNAs as a source of biomarkers, because their contents resemble those of the cell of origin. A substantial number of exosomal miRNAs have been reported as diagnostic, prognostic, or even therapeutic biomarkers in cancer patients.16–20 Therefore, exosomal miRNAs may serve as valuable non-invasive biomarkers for the diagnosis and prognosis of certain diseases.

Over the last two decades, researchers have emphasized the importance of aberrant miRNA expression, which is a relevant driving force in the initiation and progression of PCa. However, there are few studies reported on the use of exosomal miRNAs in urine specimens for diagnosis and prognosis in patients with PCa. In this study, to explore the diagnostic value of urinary exosomal miRNA for prostate cancer, next-generation sequencing (NGS) technology was used to characterize the genome-wide exosomal miRNA expression profile in urine from PCa patients and healthy controls, and quantitative real-time PCR (qRT-PCR) assay was then performed to further validate the candidate miRNAs. The flow chart of the experimental design was shown in .

Patients and Methods

Patients and Sample Collection

All urine samples were obtained from the Xijing Hospital of The Fourth Military Medical University (Xi’an, People’s Republic of China). All the patients with PCa or BPH disease enrolled in this study were newly diagnosed cases (no prior treatment). The diagnosis of PCa was confirmed by histological examination or prostate biopsy. Histopathologic Gleason scoring of the tumours was performed according to the WHO criteria. Tumours were staged according to the seventh edition of the American Joint Committee on Cancer tumour-node-metastasis (TNM) system. Clinical T-classification of PCa was divided as organ-confined (T1/T2) or non-organ-confined (T3/T4). First-catch morning urine samples (15–40 mL) were obtained from all participants without prostate rectal exam or massage, and then centrifuged at 10,000× g for 30 mins to remove cell debris and sediment. They were subsequently collected in 50 mL Eppendorf conical tubes and stored at −80°C before exosomal RNA isolation. In this study, six PCa patients and three healthy controls were used as the NGS discovery cohort. Subsequently, another 47 PCa patients, 29 BPH patients and 25 age- and gender-matched healthy individuals were used as the qRT-PCR validation cohort (Table 1). This study was approved by the Medical Ethics Committee of the Xijing Hospital of The Fourth Military Medical University (No. XJYYLL-2,015,129) and was performed in accordance with the regulatory guidelines regarding clinical assays. Informed consent was obtained from all participants or their legal guardians in this non-invasive study. This study was conducted in accordance with the Declaration of Helsinki.

Table 1

Expression of seven Significantly Deregulated miRNAs Between Localized PCa Patients and Metastatic PCa Patients Determined by NGS Technology

miRNAs	Expression Level		Up/Down	|log2(FC)|
	Localized PCa	Metastatic PCa
hsa-miR-16-2-3p	22.45	0.00	Down	3.67
hsa-miR-375	67.18	5.28	Down	17.78
hsa-miR-451a	2039.60	70.16	Down	4.86
hsa-miR-486-3p	1288.70	27.18	Down	5.92
hsa-miR-486-5p	4096.00	67.68	Down	5.57
hsa-miR-3182	20.00	1.18	Down	4.09
hsa-miR-3615	18.33	0.00	Down	17.48

Urinary Exosomes Isolation

Exosomes were isolated from urine samples using ExoQuick-TC for tissue culture media and urine (System Biosciences, Mountain View, CA, USA) according to the manufacturer’s protocol. In brief, the urine samples were thawed on ice. Subsequently, 2 mL of ExoQuick-TC reagent was added to 10 mL of urine, and the samples were thoroughly mixed by inverting three times. They were then incubated at 4°C for 12 h, followed by centrifuging at 1500×g for 30 mins. The supernatant was discarded, and the pellets were collected for RNA isolation. The presence of exosomes in the pellets was confirmed by transmission electron microscopy ().

Transmission Electron Microscopy (TEM)

An aliquot of the exosomal pellet was resuspended in phosphate-buffered saline, and a drop of the suspension was placed on a sheet of parafilm. A copper grid was placed on the drop for 2 min at room temperature and was subsequently placed onto a drop of 2% phosphotungstic acid for a 2 min-staining process. The grid was air-dried for several minutes and was examined by using a Tecnai G2 Spirit electron microscopy (FEI Co., Hillsboro, OR, USA).

Exosomal RNA Isolation

Exosomes were extracted from equal amounts of urine samples collected from healthy controls, BPH and PCa patients. RNA was isolated from the exosomes using miRNeasy Serum/Plasma kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol. To regulate the variability of exosomal miRNA expression levels, at the beginning of RNA isolation, 2 µL of cel-miR-39 (RiboBio, Guangzhou, China) was added to each sample as a spike-in control.21–23

Sequencing Library Preparation and Sequencing Data Analysis

To select miRNAs whose expression levels were altered in PCa patients compared with healthy controls, exosomal microRNA profiling of nine urine samples (6 PCa patients including 3 localized and 3 metastatic PCa patients and 3 age-matched healthy controls) was performed using Illumina NGS technology. Small RNA libraries were constructed using RNA extracted from exosomes. Index libraries were pooled equally for sequencing (Illumina HiSeq2500 platform). The exosomal miRNA RNA-seq data were processed primarily by miRBase21, which indicated miRNA types and expression levels. Exosomal miRNA profiling was normalized using read counts per million mappable miRNA sequences.

Validation of Exosomal miRNAs Using qRT-PCR

The qRT-PCR was performed using a PrimeScript RT Reagent kit and a SYBR Premix Ex Taq kit (Takara Bio, Inc., Shiga, Japan) according to the manufacturer’s protocols. Briefly, 2 µL of total RNA from each sample was reverse transcribed using a PrimeScript RT Reagent kit and specific stem-loop primers that were purchased from RiboBio. The qPCR reactions were performed on an ABI 7500 Fast Detection system (Applied Biosystems, Foster City, CA, USA) using an SYBR Premix Ex Taq kit and sequence-specific primers purchased from RiboBio. Each experiment was carried out in triplicate, and the mean value of the three-cycle threshold was used for further analysis. Cel-miR-39 was used to normalize the exosomal miRNA expression analysis, and the relative quantification analysis of exosomal miRNA was calculated using the 2−ΔΔCt method.24 Exosomal miRNAs with threshold cycle (Ct) values >35 were excluded from the analysis.

Statistical Analysis

Statistical analysis was performed using the Mann–Whitney U-test on log-transformed data between the groups. The box plots represent miRNA levels relative to cel-miR-39, transformed into quantities using the formula 2−ΔΔCt. The box plots and correlation analysis were performed using GraphPad Prism 5. Abnormally distributed data are presented as the median (IQR). P value <0.05 was considered statistically significant.

Receiver operator characteristic (ROC) curves were constructed using SPSS 16.0 to estimate the feasibility of using the specific exosomal miRNAs to differentiate between the PCa patients and the healthy controls. Meanwhile, the area under the curve (AUC) was used to test the power of using the specific exosomal miRNAs and PSA to distinguish PCa patients from BPH patients or to differentiate between localized PCa and metastatic PCa. In brief, the logistic regression was first carried out using miRNA expression levels, and the predicted probabilities were calculated for each single miRNA or all miRNAs together. The AUC was calculated with 95% confidence intervals.

Results

Expression Profiling of Urinary Exosomal miRNAs in Prostate Cancer and the Selection of Candidate Exosomal miRNAs for Validation

Morphological confirmation of exosomes isolated from urine samples was evaluated by TEM (See ). Evaluating aberrant urinary exosomal miRNA expression in PCa can provide a promising tool to identify a specific biomarker for the diagnosis and prediction of PCa. In the initial screening phase using NGS technology, urine samples were collected from six PCa patients (3 localized PCa patients and 3 metastatic PCa patients) and three healthy controls. The standardized count of sequencing reads (total sequencing tags in the library) could be used to compare miRNA expression levels between PCa patients and healthy controls. A genome-wide expression profiling of exosomal miRNAs obtained by Illumina NGS technology showed that urine from PCa patients had 39 down-regulated miRNAs and 14 up-regulated miRNAs compared with urine from the healthy controls (Table 2), and urine from metastatic PCa patients had 7 down-regulated miRNAs compared with the urine of localized PCa patients (Table 1). For validation, four significantly up-regulated miRNAs (miR-16-2-3p, miR-451a, miR-486-3p and miR-486-5p) and one down-regulated miRNA (miR-375) were selected, which showed a mean fold-change >2 between PCa patients and healthy controls, as well as between localized PCa and metastatic PCa.

Table 2

Expression of Significantly Deregulated miRNAs Between PCa Patients and Healthy Controls Determined by NGS Technology

miRNAs	Expression Level		Up/Down	|log2(FC)|
	Healthy Control	PCa
hsa-miR-16-2-3p	0.71	11.23	Up	3.99
hsa-miR-451a	128.51	1054.92	Up	3.04
hsa-miR-486-3p	27.74	657.95	Up	4.57
hsa-miR-486-5p	67.21	2081.85	Up	4.95
hsa-miR-126-5p	0.00	4.24	Up	15.37
hsa-miR-1273g-3p	7.74	43.44	Up	2.49
hsa-miR-199a-5p	3.00	19.02	Up	2.66
hsa-miR-20a-5p	5.24	26.20	Up	2.32
hsa-miR-3656	0.60	8.34	Up	3.80
hsa-miR-4492	5.39	38.21	Up	2.82
hsa-miR-4497	123.01	1018.97	Up	3.05
hsa-miR-4508	5.65	29.17	Up	2.37
hsa-miR-4532	8.54	43.11	Up	2.34
hsa-miR-9-5p	20.11	84.12	Up	2.06
hsa-miR-375	839.54	36.23	Down	4.53
hsa-let-7c-5p	103.31	6.90	Down	3.90
hsa-miR-100-5p	2703.51	215.12	Down	3.65
hsa-miR-10a-5p	3603.55	136.07	Down	4.73
hsa-miR-10b-3p	9.33	0.00	Down	16.51
hsa-miR-10b-5p	1263.99	25.27	Down	5.64
hsa-miR-125a-5p	143.39	18.04	Down	2.99
hsa-miR-125b-5p	227.43	27.48	Down	3.05
hsa-miR-148a-3p	1995.73	261.68	Down	2.93
hsa-miR-149-5p	15.13	1.08	Down	3.80
hsa-miR-151a-3p	589.58	42.22	Down	3.80
hsa-miR-152-3p	78.38	4.43	Down	4.15
hsa-miR-192-5p	1001.74	74.54	Down	3.75
hsa-miR-196a-5p	16.69	1.05	Down	3.99
hsa-miR-200a-5p	39.50	1.39	Down	4.83
hsa-miR-200b-3p	381.33	22.83	Down	4.06
hsa-miR-200b-5p	11.82	0.23	Down	5.70
hsa-miR-200c-3p	348.95	21.77	Down	4.00
hsa-miR-203a-3p	139.19	8.39	Down	4.05
hsa-miR-204-5p	289.56	19.36	Down	3.90
hsa-miR-205-5p	85.99	14.43	Down	2.58
hsa-miR-23b-3p	30.03	3.50	Down	3.10
hsa-miR-27b-3p	103.87	15.73	Down	2.72
hsa-miR-28-3p	145.02	12.22	Down	3.57
hsa-miR-30a-3p	276.16	12.15	Down	4.51
hsa-miR-30a-5p	3273.13	104.62	Down	4.97
hsa-miR-30b-5p	19.22	2.37	Down	3.02
hsa-miR-30c-5p	160.87	17.00	Down	3.24
hsa-miR-30d-5p	920.00	114.22	Down	3.01
hsa-miR-30e-3p	9.54	0.85	Down	3.49
hsa-miR-361-3p	108.73	12.48	Down	3.12
hsa-miR-365a-5p	3.86	0.00	Down	15.24
hsa-miR-429	13.27	1.40	Down	3.25
hsa-miR-509-3p	7.40	0.00	Down	16.18
hsa-miR-514a-3p	21.39	0.76	Down	4.82
hsa-miR-532-5p	294.17	24.93	Down	3.56
hsa-miR-664a-5p	12.81	0.88	Down	3.86
hsa-miR-99b-3p	21.03	0.84	Down	4.65
hsa-miR-99b-5p	490.76	30.43	Down	4.01

Validation by qRT-PCR

To further validate the sequencing data, the five differentially expressed urine exosomal miRNAs were examined by using qRT-PCR in a validation sample cohort composed of 47 PCa patients and 25 healthy controls. The clinical and demographic characteristics of the PCa patients are summarized in Table 1. qRT-PCR results demonstrated that the expression of miR-375 was significantly downregulated in urine samples of PCa patients compared with those of healthy controls (Figure 1A). In contrast, the expression levels of miR-451a, miR-486-3p and miR-486-5p were significantly upregulated in PCa samples compared with healthy controls (Figure 1C–E). More importantly, the trend of the alteration of the expression of the four miRNAs was generally concordant between the sequencing data and the validation cohort. In addition, miR-16-2-3p displayed a differential expression tendency between NGS and qRT-PCR, but there was no significant difference in the relative expression of miR-16-2-3p in PCa samples compared with samples from healthy controls (Figure 1B). Therefore, miR-16-2-3p was excluded from further study. This phase generated a panel of four miRNAs (miR-375, miR-451a, miR-486-3p and miR-486-5p) that were significantly altered in PCa patients.

Figure 1

Expression of 5 candidate exosomal miRNAs in the urine samples of the validation cohort. Relative expression levels of urinary exosomal miR-375 (A), miR-16-2-3p (B), miR-486-3p (C), miR-451a (D), and miR-486-5p (E) in patients with PCa. Data presented as relative fold changes.

Receiver operator characteristics (ROC) curves were constructed to explore the sensitivity and specificity of urinary exosomal miR-375, miR-451a, miR-486-3p and miR-486-5p in discriminating between PCa patients and healthy controls. The results suggested that the four miRNAs can discriminate between the two groups with high precision: miR-375 (AUC = 0.788; 95% CI = 0.676–0.901), miR-451a (AUC = 0.757; 95% CI = 0.641–0.872), miR-486-3p (AUC = 0.704; 95% CI = 0.576–0.833), miR-486-5p (AUC = 0.796; 95% CI = 0.690–0.901). As a result, we selected a classifier of four miRNAs to be the potential signature for PCa. The diagnostic sensitivity and specificity obtained for the validation cohort were 91% and 89%, respectively, and AUC was 0.979 for the validation cohort (Figure 2).

Figure 2

Receiver operator characteristic curve (ROC) for 4 individual miRNAs (miR-375, miR-451a, miR-486-3p and miR-486-5p) and their combination to differentiate between PCa patients and healthy controls.

Correlation of Urinary Exosomal miRNA Levels with Clinical Factors

To determine whether the four miRNA-based biomarkers were influenced by the clinical features of PCa patients, including age, Gleason score, T-stage and serum PSA, the relationships between the four urinary exosomal miRNA expression levels and clinical factors were analyzed using Spearman correlation. The urinary exosomal miR-375 level showed a correlation with the T-stage of PCa patients, while no obvious differences were observed when PCa patients were stratified by age, Gleason score, or serum PSA levels. In addition, the expression level of miR-375 was negatively correlated with the clinical T-stages of PCa, r = - 0.41. The PCa patients with lower levels of urinary exosomal miR-375 expression exhibited advanced clinical T-stages (P < 0.05).

Differentiation Between PCa Patients and BPH Patients by a Biomarker Based on 2 miRNAs

To investigate whether the four urinary exosomal miRNAs could serve as specific biomarkers to distinguish PCa from BPH, their expression levels in 29 BPH patients were measured by using qRT-PCR, and the results were compared with those from the PCa patients in the validation cohort. The clinical and demographic characteristics of the PCa patients are summarized in Table 3. The results clearly indicated that miR-375 and miR-451a could be used to separate PCa from BPH cases (Figure 3A and B). No significant differences were observed in the levels of the other two candidate miRNAs between PCa patients and BPH patients (Figure 3C and D). The ROC curve shows that the AUCs of miR-375 and miR-451a are 0.700 and 0.683, respectively, which suggests their potential efficacy in distinguishing between PCa and BPH. Moreover, miR-375 combined with miR-451a provided a better area under the curve (AUC = 0.726; 95% CI = 0.614–0.842), which means that the biomarker based on those 2 miRNAs is more sensitive in discriminating between PCa samples and BPH samples than PSA (AUC = 0.624; 95% CI = 0.487–0.761; Figure 4).

Table 3

Clinical Characteristics of Participants in the qRT-PCR Cohort

Characteristics	PCa Patients	BPH Patients	Healthy Controls
Total number	47	29	25
Age(years), median (IQR)	69.00 (65.00–72.00)	68.50 (61.25–72.00)	68.50 (61.25–71.00)
PSA(ng/mL),median (IQR)	16.91 (7.42–48.76)	2.77 (1.35–6.97)	0.93 (0.64–1.68)
Gleason score
≤6	6
7	19
≥8	22
Clinical stage
≤T2	26
>T2	21
Metastasis
No	32
Yes	15

Figure 3

Expression of urinary exosomal miRNAs in PCa patients and BPH patients. Relative expression levels of urinary exosomal miR-375 (A), miR-451a (B), miR-486-3p (C), and miR-486-5p (D). Data are presented as relative fold changes.

Figure 4

Evaluation of the ability of the miRNA-based panel and PSA to differentiate between patients with PCa and patients with BPH. Receiver operator characteristic (ROC) curve for PSA, two individual miRNAs (miR-375 and miR-451a) and their combination to differentiate between two groups consisting of 47 PCa patients and 29 BPH patients.

Differentiation Between Metastatic PCa Samples and Localized PCa Samples by miR-375

To further analyse whether the 4 miRNAs could serve as a novel biomarker to predict the progression of PCa, the 47 PCa patients in the validation cohort were stratified into 2 groups: localized PCa and metastatic PCa. The comparison shown in Figure 5A clearly suggests that miR-375 could be used to distinguish localized PCa from metastatic PCa. No significant differences were observed in the levels of the other three miRNAs between localized PCa and metastatic PCa (Figure 5B–D). ROC analysis further confirmed that miR-375 (AUC = 0.806; 95% CI = 0.680–0.932) is superior to PSA (AUC = 0.684; 95% CI = 0.510–0.859) in discriminating between localized PCa and metastatic PCa (Figure 6).

Figure 5

Expression of urinary exosomal miRNAs in localized PCa and metastatic PCa. Relative expression levels of urinary exosomal miR-375 (A), miR-451a (B), miR-486-3p (C), and miR-486-5p (D) in localized PCa patients and metastatic PCa patients. Data presented as relative fold changes.

Figure 6

Receiver-operating characteristic curve (ROC) for urinary exosomal miR-375 and PSA to differentiate between localized PCa patients and metastatic PCa patients.

Discussion

PCa has a wide diffusion and represents the second major cause of death worldwide because of its aggressive behaviour.25 MiRNAs have been suggested to be novel diagnostic/therapeutic instruments, as they could play a role as a biomarker in the diagnosis and may also represent possible targets for new therapies.26,27 In the case of PCa, the interest in miRNA is linked to the fact that prostate-specific antigen shows several limitations,28,29 as infection, very common in frail patients.30,31 Early diagnosis, especially in the high risk, as the main cause of death for PCa, is needed.32,33 The challenge nowadays is to better understand the mechanism of cancer development, finding real PCa markers and developing new specific therapies in order to reduce the mortality of PCa.34 Thus, the research on miRNA is of paramount importance.35

A large number of studies have proved that miRNAs play key roles in the pathogenesis and progression of tumours.36,37 Therefore, miRNAs can be used as molecular markers for diagnosis and prognosis. In general, using urine as a specimen for tumour biomarkers is challenging because urine contains a wide variety of biomolecules such as high concentrations of nucleases and RNases. However, exosomes, which contain miRNA, have double-lipid membranes that can protect the miRNA contained within from degradation by RNases in urine.38 In addition, urine samples can be easily collected during the routine examination process. Based on the above advantages, urinary exosomal miRNAs can be used as promising molecular markers for certain diseases. Although miRNA levels have been studied in various diseases, few comprehensive studies have been reported so far for urine exosomal miRNA-based PCa diagnosis.39,40

The aim of this study was to explore whether urine samples contain exosomal miRNAs and whether the expression profiling of these urinary exosomal miRNAs consistently differ between PCa patients and healthy controls. In this study, we investigated hundreds of known exosomal miRNAs to search for diagnostic markers for PCa by using Illumina NGS technology to analyse the urine-based profile of exosomal miRNA expression. After analysis, we selected five significantly deregulated miRNAs, which showed a mean fold-change >2 between PCa patients and healthy controls, as well as between localized PCa and metastatic PCa. The 5 candidate miRNAs were further validated in a larger cohort including 47 PCa patients and 25 healthy controls. qRT-PCR results demonstrated the upregulation of three miRNAs (miR-451a, miR-486-3p, and miR-486-5p) and the downregulation of miR-375 in PCa samples. Furthermore, the expression level of miR-375 was found to be negatively correlated with advanced clinical T-stages of PCa patients.

In our research, we found that the exosomal miR-451a level, which has been shown to be frequently downregulated in hypopharyngeal squamous cell carcinoma,41 papillary thyroid carcinoma,42 melanoma43 and gastric cancer,44 was significantly upregulated in the urine of PCa patients. Deregulation of miR-451a has not been previously reported in PCa. To our knowledge, this is the first study to show that urinary exosomal miR-451a is aberrantly expressed in PCa, which implies that miR-451a could be a non-coding oncogene in PCa, and its function needs further exploration. We found that urinary exosomal miR-486-5p and miR-486-3p levels were upregulated in PCa patients compared with healthy controls. To date, miR-486-5p and miR-486-3p have been rarely reported in PCa patients,45 which still needs further research.

For miR-375, previous studies showed its upregulation in PCa serum, PCa tissue and cell lines in comparison to healthy control serum, adjacent normal tissue and non-tumorigenic epithelial prostatic cells, respectively.46–49 Recently, Foj et al detected miR-375 in urinary exosomes and found it was significantly upregulated in PCa patients.39 However, in the present study based on NGS and qRT-PCR studies, we found an opposite result. Interestingly, in another recent study, the authors found a similar pattern. They indicated that the levels of urinary exosomal miR-196a-5p and miR-501-3p, which had been found to be mainly upregulated in PCa patients in previous studies, were significantly downregulated in PCa patients based on both NGS and qRT-PCR tests. While in our present NGS study, we achieved consistent results showing the downregulation of the two miRNAs in PCa patients. In addition, in the above-mentioned study, the entire list of NGS results showed that miR-375 was reduced in PCa patients compared with the healthy controls, which agreed with our results. It is not clear why there are such different results in urinary exosomal miRNAs studies, but the different patient cohorts using could be a possible explanation. Therefore, to confirm the findings, larger cohorts and more multi-centre studies are needed. In addition, although miR-375 has been mostly considered to be a tumour oncogene in PCa, it is worth mentioning that the recent literature has revealed that miR-375 acts either as an oncomiR or a tumour-suppressor miRNA depending on the cellular context, which seems to agree with the results in our study.

This study has demonstrated the presence of exosomal miRNAs in urine samples as in previous reports. In addition, we have demonstrated that exosomal miR-375, miR-451a, miR-486-3p and miR-486-5p are differentially expressed in urine from PCa patients, and the ROC curve demonstrates that the four miRNAs combined together have good efficacy to distinguish between healthy controls and PCa patients, with a sensitivity of 91% and a specificity of 89%. In addition, our present finding suggests that a combination of miR-375 and miR-451a has the potential to serve as a specific and sensitive molecular marker to distinguish PCa patients from BPH patients, and miR-375 alone can distinguish localized PCa patients from metastatic PCa patients to predict the progression of PCa.

Conclusion

In conclusion, we suggest that certain exosomal miRNAs in urine could serve as powerful and non-invasive tools for the diagnosis and prognosis of PCa. Further studies are needed in a larger cohort of patients to confirm these findings.